InSite Vision Sees a Better Offer

by | Aug 21, 2015 7:32 pm | Pharmaceuticals

Back in June, InSite Vision Inc. (OTCBB: INSV), which focuses on specialty ophthalmic products for diseases of the eye, agreed to be acquired by QLT Inc. (NASDAQ: QLTI) in an all-stock transaction. QLT shareholders would own about 89% of the combined company, which would retain the QLT  name and be incorporated in Canada, thanks to QLT’s base in Vancouver, British Columbia. Last week, however, InSite informed QLT that a “multi-national pharmaceutical company” had made an unsolicited bid of $0.25 per share of INSV, which the target decided was a better offer than QLT made. QLT now has to match the proposed price, or terminate the agreement. Our bets are on Valeant Pharmaceuticals (NYSE:... Read More »

Deal Volume Rose in July

by | Aug 10, 2015 8:52 am | Behavioral Health Care, Biotechnology, eHealth, Home Health & Hospice, Hospitals, Laboratories, MRI & Dialysis, Long-Term Care, Managed Care, Medical Devices, Other Services, Pharmaceuticals, Physician Medical Groups, Rehabilitation

July’s combined transaction total hit 127 deals, up 2% compared with the bang-up month of July 2014, which had 124 transactions. The Services sector had a strong performance, accounting for 60% of deal volume. Long-Term Care made up 27% of the volume overall with 34 announced transactions. That equalled the record set last July for the sector, and will probably break it as more deals come to light. The Managed Care sector posted some extra activity, although seven deals versus two deals the month prior and a year ago isn’t moving  the needle very high. July 2015 DealsShare of Total Services Behavioral Health Care32% Home Health & Hospice23% Hospitals76% Labs, MRI & Dialysis43%... Read More »

Generic Drug Market Got a Shake-Up in July

by | Aug 3, 2015 8:40 am | Pharmaceuticals

Sure, you’ve heard about Teva Pharmaceutical Industries’ (NYSE: TEVA) $40.5 billion acquisition of Allergan Generics (NYSE: AGN), announced on July 27. Less hyped was Teva Pharmaceuticals USA’s sale of 22 previously marketed generic drug brands to ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) for $25 million and a percentage of future gross profits from product sales. Earlier in the month, Indian drug maker Lupin Limited (NSE: LUPIN.NS) bought the Russian generic drug maker ZAO Biocom for an undisclosed price, and then U.S.-based generic formulator GAVIS Pharmaceuticals LLC and its manufacturing plant for $880 million. The day after the Teva/Allergan announcement, Hikma Pharmaceutical LLC... Read More »

Health Care M&A Exploded in July

by | Aug 3, 2015 8:39 am | Managed Care, Pharmaceuticals

The fireworks didn’t end on the Fourth of July, at least for the health care M&A market. Preliminary data shows deal volume rose 16% to 121 deals, compared with June’s 104 deals. Thanks to the mega-deals among health insurers and generic drug makers, deal value was approximately $166.6 billion, up 883% over June’s $16.9 billion. A full report will be published in the August issue of Health Care M&A News. Top 5 Health Care M&A Deals in July 2015 AcquirerTargetPrice Anthem, Inc. Cigna Corporation$54.2 billion Teva PharmaceuticalsAllergan Generics$40.5 billion AetnaHumana Inc. $37.0 billion Celgene CorporationReceptos, Inc. $7.2 billion Centene CorporationHealth Net, Inc. $6.8... Read More »

Indian Drug Maker Gains a Manufacturing Toehold in the U.S.

by | Jul 27, 2015 6:19 pm | Pharmaceuticals

Mumbai-based Lupin Limited (NSE: LUPIN.NS) produces a wide range of branded and generic formulations and APIs globally. Last week it paid $880 million for bought GAVIS Pharmaceuticals LLC and a subsidiary, Novel Laboratories. The acquisition enhances Lupin’s scale in the U.S. generic market and broadens its pipeline in dermatology, controlled substance products and other high-value and niche generics. Gavis had sales of $96 million in FY 2014 and currently has 66 ADA filings pending approval with the FDA, and a pipeline of more than 65 products under development. Its New Jersey-based manufacturing facility is Lupin’s first manufacturing site in the United States Read More »

Second Quarter Health Care M&A Spending Tanks

by | Jul 6, 2015 2:30 pm | Biotechnology, Pharmaceuticals

It’s still early yet, but we can say with confidence that the second quarter of 2015 doesn’t hold a candle to last year’s second quarter, at least dollar-wise. Last year, deal volume and value hit all-time highs for all previous Q2s, coming in at 325 deals and $135.8 billion in spending on those deals. This year, deal volume was fairly steady at 312 (remember, these are preliminary figures for Q2:15) but deal value plummeted 60% to $54.2 billion. We’ll have more details in the July issue of Health Care M&A News, but in the meantime, here are the biggest deals of Q2:15.  Read More »